Mylan (NASDAQ:MYL) has reported improved numbers in its fiscal Q4 and 2012 results, and it also shared news of an acquisition. For the quarter, the generic-drug company's revenue was $1.7 billion, against $1.5 billion in the same period the previous year. Net profit came in at $267 million ($0.65 per diluted share), which trumped Q4 2011's figure of $227 million ($0.53).
For the full year, the top line totaled $6.8 billion and the company netted $1.09 billion ($2.59 diluted EPS), against 2011's sales of $6.1 billion and $893 million ($2.04) net profit.
Mylan also proffered guidance for its fiscal 2013. It believes it will take in $7.0 billion-$7.4 billion in revenue and post a net profit of $1.06 billion-$1.18 billion ($2.75-$2.95 diluted EPS) for the year.
Separately, the company said it is to acquire Agila, a supplier of injectable products, from India-based Strides Arcolab. The price is $1.6 billion in cash, and the transaction is expected to be completed in Q4 2013, assuming regulatory approvals and "certain closing conditions," according to Mylan.
Fool contributor Eric Volkman and The Motley Fool have no position in Mylan. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.